戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mediated by T cells in the setting of cancer vaccine therapy.
2  develop vitiligo spontaneously or following vaccine therapy.
3  between local radiation of tumor and active vaccine therapy.
4 ng tumor cells were implanted 14 days before vaccine therapy.
5 reast cancer cells is a potential target for vaccine therapy.
6 ls (DC) ex vivo as a model system for cancer vaccine therapy.
7 nant phenotype, would be an ideal target for vaccine therapy.
8 ccur within 3 months after completion of the vaccine therapy.
9  with tumors placed before the initiation of vaccine therapy.
10 ate in the liver, limiting their efficacy in vaccine therapy.
11 l-inflamed tumors such as PDACs treated with vaccine therapy.
12 erial-derived small molecules as antigens in vaccine therapies.
13 oenvironment seems to impair the efficacy of vaccine therapies.
14 Provenge has brought new hope for anticancer vaccine therapies.
15 unosuppression toward potentiation of cancer vaccine therapies.
16 olecular adjuvants for specifically tailored vaccine therapies.
17 useful for the development of DC-based tumor vaccine therapies.
18                                              Vaccine therapy activates and expands bone marrow T-cell
19 ciple and offers new practical solutions for vaccine therapy against cancer and other diseases in whi
20                           This could advance vaccine therapy against cancer provided that precursor C
21 Gsalpha as an ideal neoantigen candidate for vaccine therapy, allele-specific inhibitors, and cyclic
22          To enhance the effectiveness of DNA vaccine therapies and make possible the treatment of est
23 his protein may prove synergistic with other vaccine therapies and targets.
24      In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the
25                                         When vaccine therapy and local radiation of tumor were used i
26 cteria as promising candidates for bacterial vaccine therapy and outline a platform for expanding thi
27                              GM-CSF and IL-2 vaccine therapy and pretreatment with gammaIFN represent
28 cluding 3 who had minimal disease at time of vaccine therapy and remain free of tumor with 16-30 mont
29                   Forty-three patients chose vaccine therapy, and 11 patients chose postoperative obs
30 ric antigen receptor T cell (CAR-T) therapy, vaccine therapy, and checkpoint inhibition in this conte
31 f infectious agents, their susceptibility to vaccine therapy, and human disease resistance.
32 e is a desperate need for safe and effective vaccines, therapies, and diagnostics for SARS- coronavir
33 uman-like platforms to study pathogens, test vaccines/therapies, and strengthen pandemic readiness.
34 immunization with single-agent or multiagent vaccine therapy appears equivalent.
35                                  Protein and vaccine therapies based on mRNA would benefit from an in
36  targeted in more than 80 recent and ongoing vaccine therapy clinical trials involving QS-21 as a cri
37 cal tumor growth and an impaired response to vaccine therapy compared with CCR5 knockout (CCR5(-/-))
38 ases of the CNS may be adversely affected by vaccine therapies designed to boost autoreactive lymphoc
39 itionally, IDO1 inhibitor in the presence of vaccine therapy did not significantly modulate intratumo
40 ll activation induced by a whole cancer cell vaccine therapy enhanced anticancer efficacy in a CD8(+)
41     Thus, HKL may be clinically effective in vaccine therapies for diseases such as allergy and asthm
42 ent important elements in the development of vaccine therapy for cancer.
43            An important issue for developing vaccine therapy for human malignancy is identifying adju
44                                              Vaccine therapy for prostate and breast cancer may have
45 ne response potentiation and dose-sparing in vaccine therapy given its exceedingly high level of pote
46                                       Cancer vaccine therapies have only achieved limited success whe
47 pports the combination of IDO1 inhibitor and vaccine therapy; however, it does not support the combin
48 one in response to successive antibiotic and vaccine therapies in a commercial fish farm.
49 Nb-PM), working in a synergistic manner with vaccine therapy in an advanced mouse melanoma model.
50 st randomized, controlled trials of adjuvant vaccine therapy in human cancer reported to date.
51                                 Although VMO vaccine therapy in surgical adjuvant setting did not pro
52    Despite the efficacy of this approach for vaccine therapy, many questions remain regarding whether
53                                Postoperative vaccine therapy may enhance IgG and IgM immune responses
54    In the setting of hepatectomy, multiagent vaccine therapy offers an advantage over single-agent th
55 uals enrolled in a trial of glycoprotein 160 vaccine therapy over the course of 3-5 years, lymphoprol
56  hypersensitivity (DTH) response to adjuvant vaccine therapy (P =.0001), and OS was significantly cor
57 ents revealed a significant OS advantage for vaccine therapy (P =.0009): 5-year OS was 39% for vaccin
58 resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1 blockade
59  during the past year with the approval of a vaccine therapy, second-line chemotherapy, and reported
60 study provides a framework for combinatorial vaccine therapies that could mount robust T cell respons
61 se who are likely to benefit from a specific vaccine therapy; this approach may benefit future clinic
62 ey parameter relevant to the optimization of vaccine therapies through noninvasive MRI-based quantifi
63 adiation in combination with active specific vaccine therapy to elicit durable antitumor responses of
64        Despite the development of preventive vaccines, therapies to treat COVID-19 and other inflamma
65 erical simulations of mixed chemo-immuno and vaccine therapy using both mouse and human parameters ar
66  However, neither radiation at this dose nor vaccine therapy was capable of inhibiting growth of 8-da
67                            IR501 therapeutic vaccine therapy was safe and well tolerated, immunogenic
68                    On multivariate analysis, vaccine therapy was the most significant prognostic vari
69 ticular, we will focus on the development of vaccine therapies, which represents, in our opinion, an
70 he 1,505 patients who were seen or who began vaccine therapy within 4 months after lymphadenectomy, a
71                                              Vaccine therapy would have the advantage of generating a